News

Promising Results Released from Clinical Trial for MF Patients

According to a press release published by Constellation Pharmaceuticals, the latest findings in the Manifest Clinical Trial of CPI-0610 in Myelofibrosis Patients was found to have a profound effect on trial participants.

MPNRF Releases 2019 Request for Proposals

The MPN Research Foundation is proud to announce the opening of our 2019 call for proposals for the MPN Challenge Grant Program.

Breaking news for ropeginterferon

The CHMP has given a positive opinion on the drug and recommended granting market authorization.

MPN Highlights from ASH 2018

Each year the American Society of Hematology (ASH) hosts their annual convention, where researchers, doctors, and organizations such as the MPN Research Foundation gather to discuss the ever-changing world of blood disorders and learn about the progress of research.

MPNRF Founder Bob Rosen Honored as MPN Hero

The MPN Heroes Celebration Event held annually at ASH is an opportunity to recognize the individuals and organizations who work hard on behalf of the MPN community and make a difference in the lives of patients living with PV, ET, and MF. Each year at this event, recipients of the MPN Heroes Recognition Program are honored based on those actions and traits that define them as heroes. This year, on November 30, 2018, the founder of the MPN Research Foundation, Bob Rosen, was honored as one of those heroes.

MPNRF Funded Abstracts to be Presented at ASH

With your support, we have funded research that has resulted in gains in our understanding of Polycythemia Vera, Essential Thrombocythemia and Myelofibrosis. The publications linked below are funded by MPNRF and will be presented at the American Society of Hematology annual meeting in San Diego this December.

University of Michigan seeks to make bone marrow imaging less painful for people with myeloproliferative neoplasms

Patients with an MPN are invited to participate in the non-invasive study

Ropeginterferon reduces JAK2 burden compared to Hydroxyurea in PV according to new study

After 1 year of treatment with ropeginterferon, the ratio of JAK2-mutated to wild-type colonies grown from bone marrow progenitors was reduced by 64%, compared to 25% in patients receiving hydroxyurea.

Increased Pentraxin-3 Correlates with the Activity of the Neoplastic Clone in Primary Myelofibrosis

FDA awards $18 million in grants for advancing treatment of rare diseases

The FDA announced on that they have awarded 12 new clinical trial research grants toward advancing the development of treatments of rare diseases.

Behind the Mystery: Living with Polycythemia Vera

MPN experts Dr. Richard T. Silver, from New York - Presbyterian/Weill Cornell Medical Center, and Dr. Srdan Verstovsek of the MD Anderson Cancer Center, to discuss the latest in patient care and clinical trials for polycythemia vera, as well as the future for those living with PV as a chronic illness.

Janssen Elects Not to Continue Agreement with Geron for Imetelstat

Today Janssen announced that they would no longer be partnering with Geron on the development of Imetelstat

MPN Research Foundation Attends 3rd Annual MPN Horizons Conference

Director of Development, Bill Crowley, and Executive Director, Michelle Woehrle, represented MPN Research Foundation at the recent MPN Horizons 2018 Conference in Prague, Czech Republic.